Menu Search
Equities

May & Baker Nigeria PLC

MAYBAKER:LAG

May & Baker Nigeria PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NGN)6.50
  • Today's Change0.50 / 8.33%
  • Shares traded304.09k
  • 1 Year change+54.76%
  • Beta0.5879
Data delayed at least 60 minutes, as of May 03 2024 14:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

May & Baker Nigeria Plc. is a pharmaceutical company, which is involved in the manufacturing, selling and distribution of human pharmaceuticals, human vaccines, and consumer products. The Company operates through two segments: Pharmaceuticals and Beverage. Pharmaceuticals segment is involved in the production and sale of human pharmaceuticals and human vaccines. Beverage segment is involved in the production of beverage drinks including bottled water. The Company provides four types of products and services, including pharmaceuticals, beverages, personal care, and contract manufacturing. Its pharmaceuticals products include anti-diabetic, anti-hypertensive, anti-infective, anti-malaria, anxiolytic, analgesic, and cough and cold. Its beverages category includes Lily Water. Its personal care product includes SMARTANS hand and surface sanitizer. It offers contract manufacturing services of pharmaceutical products to international and domestic clients through its factory, Pharma Center.

  • Revenue in NGN (TTM)19.70bn
  • Net income in NGN1.08bn
  • Incorporated1944
  • Employees364.00
  • Location
    May & Baker Nigeria PLC3/5 Sapara StreetIndustrial Estate, P M B 21049, LagosIKEJA NigeriaNGA
  • Phone+234 12121290
  • Fax+234 14962832
  • Websitehttp://www.may-baker.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.